Cell membrane-derived vesicles for delivery of therapeutic agents.
10.1016/j.apsb.2021.01.020
- Author:
Quoc-Viet LE
1
;
Jaiwoo LEE
1
;
Hobin LEE
1
;
Gayong SHIM
2
;
Yu-Kyoung OH
1
Author Information
1. College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
2. School of Systems Biomedical Science, Soongsil University, Seoul 06978, Republic of Korea.
- Publication Type:Review
- Keywords:
Blood cells;
CAR-T, chimeric antigen receptor-engineered T cell;
CRISPR, clustered regularly interspaced short palindromic repeats;
CXCR4, C-X-C chemokine receptor type 4;
Cancer cells;
Cell membrane-derived vesicles;
DC, dendritic cell;
Drug-delivery systems;
Immune cells;
Manufacturing;
Membrane engineering;
NF-κB, nuclear factor kappa B;
NIR, near infrared;
PEG, polyethylene glycol;
PLGA, poly(lactic-co-glycolic acid);
RBC, red blood cell;
Stem cells;
TCR, T-cell receptor;
TRAIL, tumor necrosis factor-related apoptosis-inducing ligand
- From:
Acta Pharmaceutica Sinica B
2021;11(8):2096-2113
- CountryChina
- Language:English
-
Abstract:
Cell membranes have recently emerged as a new source of materials for molecular delivery systems. Cell membranes have been extruded or sonicated to make nanoscale vesicles. Unlike synthetic lipid or polymeric nanoparticles, cell membrane-derived vesicles have a unique multicomponent feature, comprising lipids, proteins, and carbohydrates. Because cell membrane-derived vesicles contain the intrinsic functionalities and signaling networks of their parent cells, they can overcome various obstacles encountered
